Crop Protection's Strange Recovery: Why the Numbers Are Up and the Org Charts Are Down

The view from the search seat

Something odd is happening in crop protection, and from where we sit it's hard to miss.

At the top of the market, the phone is ringing (well, it's 2026, so the emails are coming in). Big Ag's map is being redrawn faster than at any point since the 2017 mega-mergers. Corteva and Vylor have gone their separate ways, Syngenta is heading for a Hong Kong listing and BASF Agricultural Solutions for Frankfurt. New boards, new standalone businesses, new leadership teams. Those mandates are moving.

A layer or two down, it's a different story. Roles are being folded together, good people are leaving the sector, and hiring below executive level is quieter than the headlines would suggest. R&D talent in critical areas like discovery and product safety continues to seep into neighbouring industries (we're looking at you, pharma).

So the questions we keep hearing are fair ones. How long does this last? What gets us out? And will the market even look the same when we do?

The numbers are up. The org charts are down.

Here's the uncomfortable part. By most financial measures, the majors are recovering. Bayer Crop Science grew second-quarter earnings by 30%. The pain isn't in the P&L. It's in the people.

Much of that margin has been bought with headcount. Bayer has taken out around 13,500 roles since early 2024 and cut its management population by two-thirds. Our honest read is that parts of the industry have cut past efficiency and into capability. What walks out of the door isn't a cost line. It's registration history, customer relationships and the memory of why a launch worked in one market and stalled in another.

And the market isn't giving anyone much reason to rehire. Volumes are back; pricing isn't. In North America, generics are squeezing legacy portfolios. Latin America is still where prices fall hardest. EMEA had a good spring and a dry summer. Nobody is hiring ahead of that.

Why it's sticking

Four things are keeping us here, and none of them is going away quickly.

China and India are moving up the value chain. They've set the floor price for generics in Western markets for years. Now they're registering their own molecules too, with China approving 11 new active ingredients in the first half of this year alone. That isn't a cycle. It's a shift.

Geopolitics has taken over from destocking. The Iran conflict hit fertiliser first. Crop protection may well follow, and most growers won't feel the full cost until 2027.

Regulation is moving, but not landing. The US Supreme Court has given glyphosate its firmest legal footing in years. Europe's simplification omnibus could change approvals significantly, but it isn't expected to land before the end of 2027. Few companies want to build regulatory teams for rules they can't yet read.

AI is changing what R&D looks like. Syngenta reckons it could take five years off the journey from discovery to launch. Good news for the pipeline. It also means R&D teams are being rebuilt with fewer, and different, people. The skillset we think will be most prized sits at the intersection of data and agronomic science, with critical thinking as the cherry on top.

Biologicals: still growing, no longer a free pass

Biologicals remain the bright spot, though nobody quite agrees how bright. Depending on whose definition you use, the market is worth somewhere between $9bn and nearly $20bn, so any headline number deserves a pinch of salt.

What the sources do agree on is that growth no longer guarantees a profit. North American growers are adding biologicals alongside chemistry, not instead of it. Latin America has turned into a price war. EMEA has the clearest policy prize, with the EU looking to fast-track biocontrol approvals. Meanwhile, Big Ag is buying biology rather than building it, and China looks ready to bring its generics playbook to the simpler end of the market next.

For talent, the shift is from start-up builders to integrators: people who can carry a dossier across jurisdictions and prove value alongside chemistry.

How long, and what gets us out?

Our view: the slump below leadership level runs at least through the 2027 season, with a turn more likely in late 2027 into 2028. The catalysts are identifiable, and several are already on the calendar.

The biggest catalyst is that the new standalone companies will have to grow, not just cut. New Corteva now has a dozen new actives in its pipeline, five of them biologicals. A listed Syngenta and BASF will face the same investor logic: you can't cut your way to a re-rating forever. At some point, you need people to register, launch and sell.

New chemistry reaching the market from 2027 is the second. A settled EU omnibus, a calmer Middle East and better grower margins would all help too, but none of them comes with a date.

Will we come out to the same market? No.

We think it splits into three. Leaner, focused innovators. Chinese and Indian challengers moving from supplier to brand owner across the Americas and EMEA. And biologicals specialists, increasingly folded into the majors. The legacy generics businesses of the Western majors sit awkwardly in the middle, which is why Bayer ring-fencing its US glyphosate business as Ruveon is worth watching.

What to do about it

The real risk isn't the slump. It's what happens when the recovery arrives and the people have gone. As we wrote in The Succession Gap, this cycle doesn't have the release valve that used to catch talent leaving Big Ag. When the market turns, everyone will want the same scarce profiles at once.

So, practically. If you run a business, work out now which ten or twenty roles your 2028 pipeline depends on, and who steps in if one of them walks. If you're a senior leader, don't mistake a quiet market for a closed one. The standalone businesses and globalising challengers will be building leadership teams over the next two years, and the conversations start well before the job adverts do.

Barclay Hamp works with businesses across synthetic and biological crop protection, seeds and traits, and AgTech to build leadership, commercial and R&D teams across North America, Latin America, and EMEA. If you're rethinking your organisation, or your next move, for the market that comes next, we'd welcome the conversation.